Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2021

View Archived Issues

Medshine Discovery discovers ketohexokinase inhibitors

Dual GCGR and GLP-1 agonists patented by Merck & Co.

Bristol Myers Squibb patents diacylglycerol kinase alpha/zeta inhibitors

Evaluation of a mucosal vaccine based on recombinant N. lactamica expressing heterologous antigens

T-cell exhaustion is durable, but specific

Clinical trial of AP-003 in COVID-19 approved in Chile

FDA clears IND for lanraplenib in patients with AML

Discovery novel GPR119 agonist with excellent blood glucose-lowering effects

Ghent University Hybrid CAR-T cell platform has dual anti-HIV effects

FXa-DOAC reversal with no thrombogenic potential seen with VMX-C001

Boehringer Ingelheim advances development of alteplase for COVID-19 ARDS

Infinity reports data on eganelisib in combination therapy for urothelial cancer and TNBC

New phase II trial evaluates Orpathsys for advanced or metastatic MET-amplified gastric cancer

JadiCell reduces lung injury in animal model replicating COVID-19 Delta variant inflammation

First-in-human study investigates HJV inhibitor DISC-0974 for anemia of inflammation

Dosing underway in phase I trial of AR degrader GT-20029 in China

Mouse model shows targeting RagC GTPase could safely treat B-cell lymphomas

Ipsen and BAKX Therapeutics partner on BKX-001

University of Oxford tests vaccine against plague in phase I

Eccogene begins first-in-human study of ECC-0509 for NASH and osteoarthritis pain

DiosCURE enters licensing agreement for single-domain antibodies against SARS-CoV-2

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...